NLSP

NLS Pharmaceutics Ltd. Ordinary Shares (NLSP)

About NLS Pharmaceutics Ltd. Ordinary Shares (NLSP)

NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. Its product portfolio includes Quilience, a treatment for excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol, a treatment for attention deficit hyperactivity disorder. The company was founded by Ronald Hafner, Eric Konofal, and Alexander Zwyer on June 10, 2015 and is headquartered in Zurich, Switzerland.

Details

Daily high

$2.24

Daily low

$1.78

Price at open

$2.23

52 Week High

$24.34

52 Week Low

$1.73

Market cap

4.8M

Dividend yield

0.00%

Volume

262,539

Avg. volume

560,047

P/E ratio

-10.31

NLS Pharmaceutics Ltd. Ordinary Shares News